文献速递慢性肾脏病遗传性与小管间质肾病

CDK4驱动mTORC1信号缺失下的囊性肾病进展

Cyclin-dependent kinase 4 drives cystic kidney disease in the absence of mTORC1 signaling activity.
PubMed 文献 · Kidney Int · 2024-08-31

该研究在同时敲除Kif3A和Raptor的小鼠中发现,mTORC1缺失可显著改善肾功能、减少囊肿并延长生存,但小鼠最终仍死于囊性肾病。转录组分析揭示CDK4作为替代驱动因子,抑制CDK4/6可减缓小鼠和人多囊肾病类器官模型疾病进展。

要点

  • mTORC1缺失不能完全阻止囊性肾病进展
  • CDK4是mTORC1缺失后囊肿生长的替代驱动因子
  • CDK4/6抑制剂Palbociclib可减缓多囊肾病模型进展

核心结论

  • 囊性肾病在mTORC1信号缺失后仍可通过CDK4依赖通路进展,提示需联合或序贯治疗。

研究设计与样本

  • 在Kif3A缺失导致纤毛缺陷的小鼠中同时敲除mTORC1亚基基因Raptor,观察囊肿形成、肾功能和生存。
  • 利用转录组分析、小鼠模型和人多囊肾病类器官模型评估CDK4/6抑制剂Palbociclib的效果。

主要发现

  • 与仅Kif3A缺失小鼠相比,同时缺失Raptor的小鼠肾功能、MRI检测的囊肿形成和总体生存率显著改善。
  • 同时缺失Raptor的小鼠最终仍死于囊性肾病。
  • 转录组分析显示其他促生长信号通路快速激活,CDK4被鉴定为囊肿生长的替代驱动因子。
  • Palbociclib抑制CDK4依赖信号可显著减缓小鼠和人多囊肾病类器官模型的疾病进展,并增强mTORC1缺失/抑制的效果。

临床怎么用

  • 未来临床试验需考虑联合或序贯疗法以提高囊性肾病患者疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Progression of cystic kidney disease has been linked to activation of the mTORC1 signaling pathway. Yet the utility of mTORC1 inhibitors to treat patients with polycystic kidney disease remains controversial despite promising preclinical data. To define the cell intrinsic role of mTORC1 for cyst development, the mTORC1 subunit gene Raptor was selectively inactivated in kidney tubular cells lacking cilia due to simultaneous deletion of the kinesin family member gene Kif3A. In contrast to a rapid onset of cyst formation and kidney failure in mice with defective ciliogenesis, both kidney function, cyst formation discerned by magnetic resonance imaging and overall survival were strikingly improved in mice additionally lacking Raptor. However, these mice eventually succumbed to cystic kidney disease despite mTORC1 inactivation. In-depth transcriptome analysis revealed the rapid activation of other growth-promoting signaling pathways, overriding the effects of mTORC1 deletion and identified cyclin-dependent kinase (CDK) 4 as an alternate driver of cyst growth. Additional inhibition of CDK4-dependent signaling by the CDK4/6 inhibitor Palbociclib markedly slowed disease progression in mice and human organoid models of polycystic kidney disease and potentiated the effects of mTORC1 deletion/inhibition. Our findings indicate that cystic kidneys rapidly adopt bypass mechanisms typically observed in drug resistant cancers. Thus, future clinical trials need to consider combinatorial or sequential therapies to improve therapeutic efficacy in patients with cystic kidney disease.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Grahammer F, Dumoulin B, Gulieva RE, et al. Cyclin-dependent kinase 4 drives cystic kidney disease in the absence of mTORC1 signaling activity. Kidney Int. 2024. PMID: 39218392. doi:10.1016/j.kint.2024.08.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。